Related references
Note: Only part of the references are listed.Immunologic Cold Squamous Cell Carcinomas of the Head and Neck Are Associated With an Unfavorable Prognosis
Julika Ribbat-Idel et al.
FRONTIERS IN MEDICINE (2021)
Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies
Nicola L. Lawson et al.
MODERN PATHOLOGY (2020)
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
Preeti Narayan et al.
CLINICAL CANCER RESEARCH (2020)
EVI1 as a Marker for Lymph Node Metastasis in HNSCC
Christian Idel et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges
Rita S. Moreira et al.
LIFE SCIENCES (2020)
Human T cell glycosylation and implications on immune therapy for cancer
Elien De Bousser et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies
Sylvie Lantuejoul et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plusnab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system
Rodrigo Shimabukuro Ho et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study
Spasenija Savic et al.
VIRCHOWS ARCHIV (2019)
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
Heng-Huan Lee et al.
CANCER CELL (2019)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E. W. Cohen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab
Markus Eckstein et al.
EUROPEAN JOURNAL OF CANCER (2019)
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
J. Adam et al.
ANNALS OF ONCOLOGY (2018)
PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
Enrico Munari et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming Sound Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris et al.
ORAL ONCOLOGY (2018)
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
Hongshu Sui et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Ecotropic viral integration site 1, a novel oncogene in prostate cancer
A. Queisser et al.
ONCOGENE (2017)
Blueprint 2: PD-L1 Immunohistochemistry Comparability Study in Real-Life, Clinical Samples
M. Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer
Marianne J. Ratcliffe et al.
CLINICAL CANCER RESEARCH (2017)
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
Andreas H. Scheel et al.
MODERN PATHOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Matias E. Valsecchi
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
J. D. Wolchok et al.
ANNALS OF ONCOLOGY (2013)
Share Paper
